NEXTBio Capital Management’s LB Pharmaceuticals LBRX Stock Holding History

NEXTBio Capital Management’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.22M	Buy	+68,249	New	+$2M	1.02%	20

Other funds holding LBRX

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

JP Morgan Chase

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Spruce Street Capital New York $510M AUM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

NEXTBio Capital Management's LBRX Position: Q2 2026 in Review

NEXTBio Capital Management opened a new position in LB Pharmaceuticals (LBRX) in Q2 2026: 68,249 shares worth $2.22M. The stake represents 1.02% of the portfolio and ranks #20 among its holdings.

115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

NEXTBio Capital Management held 68,249 shares of LB Pharmaceuticals worth $2.22M as of Q2 2026.
LB Pharmaceuticals was a new NEXTBio Capital Management position in Q2 2026.
LB Pharmaceuticals made up 1.02% of NEXTBio Capital Management's portfolio in Q2 2026, its #20 holding.
115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on NEXTBio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.